Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Shares Outstanding for 12 consecutive years, with $70000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding fell 99.95% year-over-year to $70000.0, compared with a TTM value of $70000.0 through Dec 2025, down 99.95%, and an annual FY2025 reading of $70000.0, down 99.95% over the prior year.
  • Shares Outstanding was $188.3 million for Q4 2025 at Heron Therapeutics, up from $183.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $188.3 million in Q4 2025 and bottomed at $91.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $132.7 million, with a median of $130.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding grew 26.36% in 2024, then plummeted 99.95% in 2025.
  • Year by year, Shares Outstanding stood at $102.0 million in 2021, then increased by 16.81% to $119.2 million in 2022, then rose by 26.13% to $150.3 million in 2023, then increased by 1.23% to $152.1 million in 2024, then tumbled by 99.95% to $70000.0 in 2025.
  • Business Quant data shows Shares Outstanding for HRTX at $70000.0 in Q4 2025, $524000.0 in Q3 2025, and $153.3 million in Q2 2025.